Drug Approval | September 30, 2023
Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 manufacturing facility
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Ronco succeeds Dr. Christine Dingivan, who will now serve as a senior advisor to Executive Chairman Sastry Chilukuri
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
The inspection classification was determined by the agency as Voluntary Action Indicated
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Eris Lifesciences enters into term loan agreement with Citi Bank
With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility
Subscribe To Our Newsletter & Stay Updated
